We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+18.11%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.92B
AUM Growth
+$563M
Cap. Flow
+$657M
Cap. Flow %
13.36%
Top 10 Hldgs %
40.18%
Holding
111
New
29
Increased
28
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$126M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$95.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$76.9M
4
BIO icon
Bio-Rad Laboratories Class A
BIO
+$72.2M
5
PRTA icon
Prothena Corp
PRTA
+$62.2M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$186M
2
JNJ icon
Johnson & Johnson
JNJ
+$160M
3
MCK icon
McKesson
MCK
+$127M
4
UNH icon
UnitedHealth
UNH
+$124M
5
ABBV icon
AbbVie
ABBV
+$116M

Sector Composition

Rank Sector Weight
1 Healthcare 90.36%
2 Financials 0.49%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSAC
76
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$5.15M 0.1%
520,000
– –
BLSA
77
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$5.01M 0.1%
500,000
– –
LENZ
78
LENZ Therapeutics
LENZ
$184M
$4.99M 0.1%
225,000
+123,571
+122% +$2.94M
ARYD
79
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$4.96M 0.1%
500,000
– –
PANA
80
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
$4.9M 0.1%
500,000
– –
CMPX icon
81
Compass Therapeutics
CMPX
$367M
$4.56M 0.09%
2,000,000
– –
EPIX
82
DELISTED
ESSA Pharma
EPIX
$4.48M 0.09%
2,460,000
– –
OBIO icon
83
Orchestra BioMed
OBIO
$231M
$3.96M 0.08%
400,000
– –
CYT
84
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$3.47M 0.07%
1,806,200
-43,800
-2% -$114K
TNGX icon
85
Tango Therapeutics
TNGX
$4.34B
$2.95M 0.06%
813,700
+60
+0% +$256
SCYX icon
86
SCYNEXIS
SCYX
$36M
$2.74M 0.06%
142,575
+22,634
+19% +$443K
DNAD
87
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$1.96M 0.04%
200,000
– –
DNAB
88
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
$1.96M 0.04%
200,000
– –
ONCS
89
DELISTED
OncoSec Medical Incorporated
ONCS
$1.44M 0.03%
133,864
– –
HYPR icon
90
Hyperfine
HYPR
$90.9M
$1.22M 0.02%
1,503,754
– –
ACIU icon
91
AC Immune
ACIU
$236M
$869K 0.02%
+274,876
New +$866K
REUN
92
DELISTED
Reunion Neuroscience Inc. Common Shares
REUN
$851K 0.02%
595,200
– –
WGS icon
93
GeneDx Holdings
WGS
$1.84B
$834K 0.02%
28,788
– –
PHAS
94
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$768K 0.02%
4,361,365
-43,635
-1% -$44.5K
SNCE
95
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$692K 0.01%
21,500
– –
NUVB.WS
96
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$18K ﹤0.01%
99,999
– –
MSACW
97
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$1K ﹤0.01%
57,770
– –
ABBV icon
98
AbbVie
ABBV
$465B
– –
-755,000
Closed -$116M
ARKG icon
99
ARK Genomic Revolution ETF
ARKG
$1.54B
– –
-750,000
Closed -$23.6M
JNJ icon
100
Johnson & Johnson
JNJ
$643B
– –
-900,200
Closed -$160M
1 2 3
4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2022 Portfolio in Review

As of Q3 2022, Avidity Partners Management held 111 positions worth $4.92B, up 13% from $4.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Avidity Partners Management deployed $657M of net new capital in Q3 2022, opening 29 new positions and adding to 28 existing holdings. Its largest new stake was Sarepta Therapeutics: 948,200 shares worth $105M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was AstraZeneca, an estimated $186M trimmed.

  • Avidity Partners Management's largest Q3 2022 buy was Sarepta Therapeutics: 948,200 shares worth $105M.
  • Avidity Partners Management added most to Eli Lilly in Q3 2022, an estimated $126M increase.
  • Avidity Partners Management's biggest Q3 2022 reduction was AstraZeneca, cutting an estimated $186M.
  • Avidity Partners Management fully exited Johnson & Johnson in Q3 2022, selling an estimated $160M.
  • Avidity Partners Management's ten largest holdings make up 40% of its $4.92B portfolio in Q3 2022.
  • Avidity Partners Management opened 29 new positions and closed 14 in Q3 2022.
  • Avidity Partners Management's portfolio value rose 13% quarter-over-quarter to $4.92B.

Based on Avidity Partners Management's 13F filing for Q3 2022, filed 14 Nov 2022.